TSND-201 (methylone) for PTSD: Initial Results from Open-Label Study (IMPACT-1)

Poster presented at American College of Neuropsychopharmacology in December 2023. Conclusions: TSND-201 demonstrated rapid, robust, and durable effects on PTSD symptoms; however, limitations of this study include an open-label design and small sample size. PTSD symptom remission and response occurred rapidly after treatment with TSND-201. Rapid improvement on depressive symptoms occurred concurrently with PTSD symptom improvement. TSND-201 was generally safe and well tolerated, the most common AE was headache. This study supports further development of TSND-201 as a treatment for PTSD. Part B of IMPACT-1, a randomized, placebo-controlled study, is currently enrolling. View Poster

The release as fetched from its publisher. transcendtherapeutics.com ↗